Cargando…

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer

BACKGROUND: Even though trastuzumab is an effective therapy in early stage Her-2+ breast cancer, 40–50% of advanced Her-2+ breast cancer patients develop trastuzumab resistance. A potential resistance mechanism is aberrant downstream signal transmission due to loss of phosphatase and tensin homologu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gschwantler-Kaulich, Daphne, Tan, Yen Y., Fuchs, Eva-Maria, Hudelist, Gernot, Köstler, Wolfgang J., Reiner, Angelika, Leser, Carmen, Salama, Mohamed, Attems, Johannes, Deutschmann, Christine, Zielinski, Christoph C., Singer, Christian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333838/ https://www.ncbi.nlm.nih.gov/pubmed/28253285 http://dx.doi.org/10.1371/journal.pone.0172911

Ejemplares similares

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
por: Hudelist, G, et al.
Publicado: (2003)

Patient satisfaction after breast cancer surgery: A prospective clinical trial
por: Leser, Carmen, et al.
Publicado: (2020)

Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases
por: Leser, Carmen, et al.
Publicado: (2022)

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
por: Deutschmann, Christine, et al.
Publicado: (2022)

HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2016)

Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"
por: Deutschmann, Christine, et al.
Publicado: (2023)

Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study
por: Leser, Carmen, et al.
Publicado: (2023)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Yokoyama, Daiju, et al.
Publicado: (2021)

Cadherin-11 expression is upregulated in invasive human breast cancer
por: Pohlodek, Kamil, et al.
Publicado: (2016)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Author Correction: PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Yokoyama, Daiju, et al.
Publicado: (2021)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study
por: Gebhart, P, et al.
Publicado: (2023)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
por: Sorscher, Steven
Publicado: (2013)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
por: Nahta, Rita
Publicado: (2012)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
por: Mann, K, et al.
Publicado: (2016)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
por: Ye, Xingming, et al.
Publicado: (2014)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
por: Di Lauro, Vincenzo, et al.
Publicado: (2012)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
por: Rodríguez, Cristina E., et al.
Publicado: (2015)

Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers
por: Rieder, Viktoria, et al.
Publicado: (2015)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients
por: Singer, Christian F., et al.
Publicado: (2019)

Trastuzumab resistance induces EMT to transform HER2(+) PTEN(−) to a triple negative breast cancer that requires unique treatment options
por: Burnett, Joseph P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g2jok45olodcq21fe0bb71t4k5